Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

232
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

317
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
317
Autoimmune Disorders01:29

Autoimmune Disorders

569
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
569

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Neurology·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

JAMA neurology·2026
Same author

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.

Brain : a journal of neurology·2026
Same journal

[New approaches to nursing practice and the management of heart failure].

Soins; la revue de reference infirmiere·2026
Same journal

[Post-hospitalization educational programs: complementary or redundant?]

Soins; la revue de reference infirmiere·2026
Same journal

[End-of-life care for heart failure: realities in the hospital setting].

Soins; la revue de reference infirmiere·2026
Same journal

[Screening for frailty in heart failure patients under remote monitoring and coordination of the care pathway by the registered nurse].

Soins; la revue de reference infirmiere·2026
Same journal

[The impact of extended travel abroad on patients with heart failure].

Soins; la revue de reference infirmiere·2026
Same journal

[A low-sodium diet for heart failure: necessary or harmful?]

Soins; la revue de reference infirmiere·2026
See all related articles

Related Experiment Video

Updated: Aug 3, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K

[Multiple sclerosis treatments].

Thibault Moreau1

  • 1Service de neurologie, Centre hospitalier universitaire François-Mitterrand Dijon Bourgogne, 2B boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France; Centre de ressources et de compétences sclérose en plaques Bourgogne-Franche-Comté, Centre hospitalier universitaire François-Mitterrand Dijon Bourgogne, 2B boulevard Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France.

Soins; La Revue De Reference Infirmiere
|April 10, 2023
PubMed
Summary
This summary is machine-generated.

Effective multiple sclerosis treatments introduced over the last 30 years can reduce relapses and slow disease progression. Early, tailored, and monitored treatment is crucial for managing multiple sclerosis (MS).

Keywords:
background treatmentclinical monitoringprincipe thérapeutiquerelapse treatmentsurveillance cliniquesymptomatic treatmenttherapeutic principletraitement de fondtraitement des pousséestraitement symptomatique

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.8K

Related Experiment Videos

Last Updated: Aug 3, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.8K

Area of Science:

  • Neurology
  • Immunology

Context:

  • Multiple Sclerosis (MS) management has evolved significantly over the past three decades.
  • Disease-modifying therapies (DMTs) are now available to alter the course of MS.

Purpose:

  • To outline the advancements in multiple sclerosis treatment over the last 30 years.
  • To emphasize the importance of early, individualized, and monitored therapeutic interventions.

Summary:

  • Recent decades have seen the development of treatments that significantly decrease relapse frequency and slow the progression of multiple sclerosis.
  • Optimal outcomes require early initiation of disease-modifying therapies, selected based on the specific MS form.
  • Active monitoring and symptomatic treatments are essential components of comprehensive MS care.

Impact:

  • These advancements offer improved long-term prognoses for individuals with multiple sclerosis.
  • Highlighting the need for timely and personalized treatment strategies can enhance patient quality of life and reduce disability progression.